SCHEMBL18656864

SCHEMBL18656864

O=C1CC(=O)N(CC(F)c2cc(F)cc(Cl)c2)C(=O)N1CCc1cc(F)cc(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ USP2 O75604 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ METAP2 P50579 3/20 0.32
▸ PTGDR2 Q9Y5Y4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10159222 0.89 DRD2 (0.30) MAPTMEN1USP2KMT2AKDM4E
SCHEMBL10159246 0.89 DRD2 (0.30) MAPTMEN1USP2KMT2AKDM4E
SCHEMBL10159233 0.89 DRD2 (0.30) MAPTMEN1USP2KMT2AKDM4E
SCHEMBL18250130 0.82 RAPGEF4 (0.30) —
SCHEMBL18250140 0.82 RAPGEF4 (0.30) —
SCHEMBL18250136 0.82 RAPGEF4 (0.30) —
SCHEMBL10159133 0.80 MAPT (0.33) MAPTMEN1USP2KMT2AGAA
SCHEMBL10159296 0.80 MAPT (0.33) MAPTMEN1USP2KMT2AGAA
SCHEMBL10159221 0.80 MAPT (0.33) MAPTMEN1USP2KMT2AGAA
SCHEMBL18656955 0.78 MAPT (0.50) MAPTMEN1USP2KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144299-A1 PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Cambria Pharmaceuticals, Inc. (US) 2017-03-22 — — EP disclosed
Send feedback